Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Core Insights - Insight Molecular Diagnostics Inc. has rebranded from Oncocyte Corporation and relocated its headquarters to Nashville, Tennessee, with a new stock symbol "IMDX" effective June 18, 2025 [1][2][3] Company Strategy - The rebranding reflects the company's expanded strategic direction beyond oncology, now including a focus on transplant medicine, aiming to deliver a molecular diagnostic kit for kidney transplant patients [2][3] - The company targets a $1 billion addressable market for transplant rejection testing and is transitioning from product development to commercialization [3][4] Operational Changes - The relocation to Nashville aligns operations with the company's CLIA-certified lab and healthcare innovation hub, while maintaining a laboratory in Göttingen, Germany [4] - The company is unifying its transplant diagnostics under the GraftAssure brand, retiring the VitaGraft name [11][16] Product Development - The GraftAssure product line includes GraftAssureCore (lab-developed test), GraftAssureIQ (research-use-only kit), and GraftAssureDx (in vitro diagnostic kit in development) [11][12][16] - The company is actively participating in the European Society for Organ Transplantation (ESOT) Congress to promote its GraftAssureIQ pilot site program [7][9] Branding and Identity - The new logo symbolizes the company's commitment to healthcare providers and reflects its mission to provide insights through science [5][6] - The rebranding leverages existing rights to the name Insight Genetics, acquired in 2020, and emphasizes a healthcare provider-centric philosophy [5][6]